contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-the-presentation-of-cantargias-interim-report-january-september-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.

Cantargia

Cantargia AB (publ) (Nasdaq Stockholm: CANTA) will publish the company’s interim report for the first nine months of 2025 on Wednesday, November 19, 2025, at 07:00 a.m. CET.In conjunction to...

<div class="mfn-preamble"><p><strong>Cantargia AB (publ) (Nasdaq Stockholm: CANTA) will publish the company’s interim report for the first nine months of 2025 on Wednesday, November 19, 2025, at 07:00 a.m. CET.</strong></p></div><div class="mfn-body"><p>In conjunction to the report, investors, analysts, and media are invited to an audiocast with teleconference (in English) on November 19, at 3:00 p.m. CET, where Cantargia’s CEO Hilde Steineger, CMO Wolfram Dempke, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&amp;A-session.</p><p>If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: <a rel="noopener" href="https://cantargia.events.inderes.com/q3-report-2025">https://cantargia.events.inderes.com/q3-report-2025</a>.</p><p>If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.<br><a rel="noopener" href="https://events.inderes.com/cantargia/q3-report-2025/dial-in">https://events.inderes.com/cantargia/q3-report-2025/dial-in</a>.</p><p>The webcast will also be available on demand on Cantargia’s corporate website: <a rel="noopener" href="https://cantargia.com/en/investors/financial-reports">www.cantargia.com</a>.</p></div><div class="mfn-footer mfn-contacts mfn-47db31b9c771"><p><strong class="mfn-heading-1">For further information, please contact</strong><br>Hilde Steineger, CEO<br>Telephone: +46 (0)46-275 62 60<br>E-mail: <a rel="noopener" href="mailto:info@cantargia.com">info@cantargia.com</a></p></div><div class="mfn-footer mfn-about mfn-1508b27957df"><p><strong class="mfn-heading-1">About Cantargia</strong><br>Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.<br>&nbsp;<br>Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at&nbsp;<a rel="noopener" href="https://cantargia.com/en">www.cantargia.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/4d296dc1-8851-4655-8382-c851e5a034f6/invitation-to-the-presentation-of-cantargias-interim-report-january-september-2025.pdf" class="mfn-generated mfn-primary">Invitation to the Presentation of Cantargia’s Interim Report January-September 2025</a></p></div>

Invitation to the Presentation of Cantargia’s Interim Report January-September 2025